Collaboration, License and Other Arrangements - Additional Information (Details) - USD ($) $ in Millions |
3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Acquired in-process research and development expenses | $ 21.4 | $ 2.2 | $ 21.9 | $ 22.0 | |
| CRISPR JDCA | |||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Acquired in-process research and development expenses | $ 0.0 | $ 0.0 | $ 0.0 | $ 12.5 | |
| Proceeds from upfront payment | $ 12.5 | ||||
| CRISPR | |||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Allocation of net profits and net losses, percent | 40.00% | 40.00% | |||
| Collaborative arrangement, allocation of research and development expenses, percent | 40.00% | 40.00% | |||